Cargando…

Corneal Toxicity Induced by ABT-414 Therapy for Glioblastoma Multiforme: A Case Report

BACKGROUND: To describe a case of corneal toxicity associated with the use of the epidermal growth factor receptor (EGFR) inhibitor ABT-414 in the treatment of glioblastoma multiforme. CASE PRESENTATION: Case report of a 56-year-old male with glioblastoma multiforme who developed mild painless blurr...

Descripción completa

Detalles Bibliográficos
Autores principales:	Eshraghi, Hamoon, Mantopoulos, Dimosthenis, Suh, Leejee H., Zaldana, Francisco, Fine, Howard F.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	S. Karger AG 2018
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6323377/ https://www.ncbi.nlm.nih.gov/pubmed/30631275 http://dx.doi.org/10.1159/000494713

Ejemplares similares

Ocular Side Effects of EGFR-Inhibitor ABT-414 in Recurrent Glioblastoma: A Long-Term Safety Study
por: Parrozzani, Raffaele, et al.
Publicado: (2020)

ACT-26 ABT-414 (DEPATUX-M) IN NEWLY DIAGNOSED AND RECURRENT GLIOBLASTOMA: WHERE DO WE STAND?
por: Preusser, Matthias
Publicado: (2019)

Corneal side effects induced by EGFR-inhibitor antibody–drug conjugate ABT-414 in patients with recurrent glioblastoma: a prospective clinical and confocal microscopy study
por: Parrozzani, Raffaele, et al.
Publicado: (2020)

Efficacy of depatuxizumab mafodotin (ABT-414) monotherapy in patients with EGFR-amplified, recurrent glioblastoma: results from a multi-center, international study
por: van den Bent, Martin, et al.
Publicado: (2017)

Efficacy and safety results of depatuxizumab mafodotin (ABT‐414) in patients with advanced solid tumors likely to overexpress epidermal growth factor receptor
por: Goss, Glenwood D., et al.
Publicado: (2018)

Chemoirradiation for Glioblastoma Multiforme: The National Cancer Institute Experience
por: Ho, Jennifer, et al.
Publicado: (2013)

Synergism of a novel MCL-1 downregulator, acriflavine, with navitoclax (ABT-263) in triple-negative breast cancer, lung adenocarcinoma and glioblastoma multiforme
por: Lee, Anbok, et al.
Publicado: (2021)

Glioblastoma Multiforme
por: Sheehan, Jonas M., et al.
Publicado: (2012)

Glioblastoma Multiforme Therapy and Mechanisms of Resistance
por: Ramirez, Yulian P., et al.
Publicado: (2013)

Emerging Cellular Therapies for Glioblastoma Multiforme
por: Choi, Paul J, et al.
Publicado: (2018)

BCNU for recurrent glioblastoma multiforme: efficacy, toxicity and prognostic factors
por: Reithmeier, Thomas, et al.
Publicado: (2010)

Current Trends in Targeted Therapies for Glioblastoma Multiforme
por: Ohka, Fumiharu, et al.
Publicado: (2012)

Innovative Therapies against Human Glioblastoma Multiforme
por: Cimini, Annamaria, et al.
Publicado: (2011)

The role of metabolic therapy in treating glioblastoma multiforme
por: Maroon, Joseph C., et al.
Publicado: (2015)

Dexamethasone in Glioblastoma Multiforme Therapy: Mechanisms and Controversies
por: Cenciarini, Marta, et al.
Publicado: (2019)

Using Light for Therapy of Glioblastoma Multiforme (GBM)
por: Vasilev, Alex, et al.
Publicado: (2020)

Glioblastoma multiforme – an overview
por: Urbańska, Kaja, et al.
Publicado: (2014)

Incidentalomas to glioblastoma multiforme
por: Sachdev, Bobby, et al.
Publicado: (2014)

Evaluation of Concurrent Radiation, Temozolomide and ABT-888 Treatment Followed by Maintenance Therapy with Temozolomide and ABT-888 in a Genetically Engineered Glioblastoma Mouse Model
por: Lemasson, Benjamin, et al.
Publicado: (2016)

Understanding cytoskeleton regulators in glioblastoma multiforme for therapy design
por: Masoumi, Samaneh, et al.
Publicado: (2016)

Scientific opinion on flavouring group evaluation 414 (FGE.414): 2‐hydroxy‐4‐methoxybenzaldehyde
por: Younes, Maged, et al.
Publicado: (2021)

Tectal plate glioblastoma multiforme
por: Nemer, Michael D., et al.
Publicado: (2011)

Bilateral cystic glioblastoma multiforme
por: Kumar, Sushil, et al.
Publicado: (2013)

Glioblastoma Multiforme Stem Cells
por: Dimov, Irena, et al.
Publicado: (2011)

Atypical Presentation of Glioblastoma Multiforme
por: Al-Janabi, Wissam, et al.
Publicado: (2018)

Nanotechnology for Treatment of Glioblastoma Multiforme
por: Michael, Justin S., et al.
Publicado: (2018)

The complement system in glioblastoma multiforme
por: Bouwens van der Vlis, T. A. M., et al.
Publicado: (2018)

Temozolomide resistance in glioblastoma multiforme
por: Lee, Sang Y.
Publicado: (2016)

Survival Analysis of Glioblastoma Multiforme
por: Witthayanuwat, Supapan, et al.
Publicado: (2018)

Advances in Immunotherapy for Glioblastoma Multiforme
por: Huang, Boyuan, et al.
Publicado: (2017)

Targeted Nanotechnology in Glioblastoma Multiforme
por: Glaser, Talita, et al.
Publicado: (2017)

Prion Protein in Glioblastoma Multiforme
por: Ryskalin, Larisa, et al.
Publicado: (2019)

Current Immunotherapies for Glioblastoma Multiforme
por: Huang, Boyuan, et al.
Publicado: (2021)

Glioblastoma Multiforme Masquerading as Stroke
por: Remley, William, et al.
Publicado: (2021)

Advances in immunotherapy for glioblastoma multiforme
por: Mahmoud, Ahmad Bakur, et al.
Publicado: (2022)

Partial thickness subfoveal hole in a patient treated with tamoxifen: a case report and review of the literature
por: Sohn, Ashley, et al.
Publicado: (2022)

Glioblastoma multiforme in childhood: a case report
por: Borgo, Mauro Cruz Machado, et al.
Publicado: (2010)

Congenital glioblastoma multiforme--report of an autopsy case.
por: Jung, W. H., et al.
Publicado: (1990)

An update of advanced nanoplatforms for Glioblastoma Multiforme Management
por: Amaral, Mariana, et al.
Publicado: (2021)

Simultaneous impact of atorvastatin and mesenchymal stem cells for glioblastoma multiform suppression in rat glioblastoma multiform model
por: Goodarzi, Arash, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_rc55lplkkkmcerit1opg8rqr6l